Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is RTI Surgical a Good Buy? The Newly-Formed Hedge Fund Thinks So

Is RTI Surgical a good buy? Glen Capital Partners was established earlier this year, and is a Massachusetts-located hedge fund managed by Greg Summe. In a recent filing with the Securities and Exchange Commission, Glen Capital Partners Fund I (a fund under its umbrella) disclosed ownership of 3.5 million shares of RTI Surgical Inc (NASDAQ:RTIX), a company engaged in processing of human tissue such as musculoskeletal tissue and surgical implanting. The value of Glen Capital’s stake amounts to 13.1 million. The position represents 6.2% of the company.

RTI Surgical Inc (NASDAQ:RTIX)

For the second quarter of the year, RTI Surgical’s revenues fell by 6% on the year and amounted to $42.3 million. The company also reported a loss of $3.0 million, equivalent to $0.05 per share, versus a positive net income of $1.3 million announced for the same period of last year.

By initiating a stake in RTI Surgical, Glen Capital Partners joined several hedge funds that also disclosed ownership of the company’s shares in the latest round of 13F filings. According to our database, the hedge fund with one of the largest stakes is Royce & Associates, managed by Chuck Royce, which held almost 1.2 million shares at the end of last quarter. It is followed by Jim Simons’ Renaissance Technologies, which owns 651,600 shares, and Israel Englander’s Millennium Management, with some 481,900 shares, among others.

Recommended Reading:

Here’s What This $22 Billion Money Manager Has Been Buying and Selling

Why Bill Ackman Could Boost This Stock By 35%

My Top 2 Bill Gates Picks

Disclosure: none

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!